NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

Media Release

Zug, 24 June 2016

Shareholders' Meeting approved all proposals by the Board of Directors

At today's ordinary Shareholder's Meeting of HBM Healthcare Investments Ltd the Shareholders approved all of the proposals submitted by the Board of Directors. A total of 41% of all shares were represented at the Shareholders' Meeting.

Along with the reduction of the share capital by means of the cancellation of 400'000 registered shares, the Shareholders also approved a withholding tax-exempt distribution from the reserve from capital brought in of CHF 5.50 per share. The cash payment to shareholders will be made on 30 June 2016. Until 27 June 2016, the shares will be traded with entitlement for the cash distribution (as from 28 June 2016 without such entitlement, ex-date).

After the registration of the reduction of share capital in the commercial register, which is expected to take place early in September 2016, the share capital of HBM Healthcare Investments Ltd will amount to CHF 427,05 million, divided into 7,3 million registered shares with a par value of CHF 58.50 each.

In addition, the Shareholders' Meeting approved a new share buy-back programme that extends to a maximum of 10% outstanding shares, which will be launched after the termination of the 2014 share buy-back programme.

The Chairman of the Board of Directors, the Members of the Board of Directors as well as the Members of the Compensation Committee were all re-elected for a further term of one year. The Shareholders also approved the proposed compensation to the Board of Directors and to the Management.

The presentation shown at the Shareholders' Meeting is available on our website www.hbmhealthcare.com.

For further information, please contact Dr Andreas Wicki, tel.: +41 41 710 75 77, andreas.wicki@hbmhealthcare.com.

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of some 25 promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors, and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.